ABIVAX Société Anonyme (FRA:2X1)

Germany flag Germany · Delayed Price · Currency is EUR
70.30
-0.80 (-1.13%)
Last updated: Sep 29, 2025, 8:19 AM CET
-1.13%
Market Cap5.36B
Revenue (ttm)6.02M
Net Income (ttm)-195.39M
Shares Outn/a
EPS (ttm)-3.09
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume52
Open70.30
Previous Close71.10
Day's Range70.30 - 70.30
52-Week Range4.58 - 77.60
Betan/a
RSI56.65
Earnings DateDec 15, 2025

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2013
Employees 69
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 2X1
Full Company Profile

Financial Performance

In 2024, ABIVAX Société Anonyme's revenue was 10.79 million, an increase of 135.94% compared to the previous year's 4.57 million. Losses were -176.24 million, 19.3% more than in 2023.

Financial Statements

News

There is no news available yet.